The American Kratom Association (AKA) has welcomed a new American Medical Association (AMA) policy highlighting public health risks from highly concentrated 7-hydroxymitragynine (7-OH) products, but warns that imprecise language could mislead policymakers and consumers. In a statement released on June 10, 2026, the AKA argued that the AMA repeatedly labels these chemically manipulated opioids as “kratom products,” despite their fundamental differences from traditional kratom leaf.finance.
AKA policy fellow Mac Haddow stressed that natural kratom contains only trace levels of 7-OH, whereas some new products chemically convert mitragynine into powerful 7-OH opioids with dramatically different pharmacological profiles. The group pointed to FDA‑supervised human dosing research in which participants consumed up to 12 grams of kratom leaf without serious adverse events, underscoring the need to separate synthetic 7-OH formulations from botanical kratom in regulation. Read the original report via Yahoo Finance.
